tert-butyl N-[(3S)-1-[3-fluoro-6-[6-(6-methylpyrazin-2-yl)pyrazolo[4,3-c]pyridin-1-yl]-2-pyridyl]-3-piperidyl]carbamate → (S)-1-(3-fluoro-6-(6-(6-methylpyrazin-2-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)piperidin-3-amine

HRID 57916ノート

反応式

HRID 57916 の反応式
[F:1][C:2]1[C:3]([N:24]2[CH2:29][CH2:28][CH2:27][C@H:26]([NH:30]C(=O)OC(C)(C)C)[CH2:25]2)=[N:4][C:5]([N:8]2[C:16]3[CH:15]=[C:14]([C:17]4[CH:22]=[N:21][CH:20]=[C:19]([CH3:23])[N:18]=4)[N:13]=[CH:12][C:11]=3[CH:10]=[N:9]2)=[CH:6][CH:7]=1>C(O)(C(F)(F)F)=O.ClCCl>[F:1][C:2]1[C:3]([N:24]2[CH2:29][CH2:28][CH2:27][C@H:26]([NH2:30])[CH2:25]2)=[N:4][C:5]([N:8]2[C:16]3[CH:15]=[C:14]([C:17]4[CH:22]=[N:21][CH:20]=[C:19]([CH3:23])[N:18]=4)[N:13]=[CH:12][C:11]=3[CH:10]=[N:9]2)=[CH:6][CH:7]=1

参加物

4

実験手順

A mixture of tert-butyl N-[(3S)-1-[3-fluoro-6-[6-(6-methylpyrazin-2-yl)pyrazolo[4,3-c]pyridin-1-yl]-2-pyridyl]-3-piperidyl]carbamate (0.1345 mmol; 113.1 mg) in TFA (1 mL) and dichloromethane (4 mL) was stirred at room temperature overnight. The mixture was concentrated and the residue was purified by reverse phase HPLC to afford 215 as an off-white solid (42.7 mg, 77%). 1H NMR (400 MHz, DMSO) δ 9.58-9.55 (s, 1H), 9.47-9.43 (s, 1H), 9.33-9.30 (s, 1H), 8.69-8.65 (s, 1H), 8.64-8.62 (s, 1H), 8.35-8.30 (s, 1H), 7.79-7.72 (dd, J=12.7, 8.5 Hz, 1H), 7.42-7.38 (dd, J=8.4, 2.0 Hz, 1H), 4.05-3.97 (d, J=8.5 Hz, 2H), 3.29-3.26 (d, J=10.8 Hz, 1H), 3.02-2.95 (m, 2H), 2.66-2.60 (s, 3H), 2.00-1.87 (t, J=14.1 Hz, 2H), 1.80-1.67 (m, 1H), 1.47-1.37 (d, J=10.5 Hz, 1H); MS (ESI) m/z: 405.1 [M+H]+

後処理

  1. concentrationThe mixture was concentrated
  2. customthe residue was purified by reverse phase HPLC

出典と根拠

ORDレコード
ord-548cc4c00bf946a088288af0d73b3b6a
出典データセット
uspto-grants-2016_09
特許番号
US09434725B2

反応ノート

読み込み中…